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Abstract A gene encoding a single-chain antibody fragment
directed against digoxin (named 1C10 scFv) was cloned in two
expression systems. For this purpose, a new baculovirus transfer
cassette fully compatible with the procaryotic pHEN vector was
constructed. Baculovirus production led to higher yield than did
Escherichia coli expression. The procaryotic fragment showed
variations in the fine specificity profile but an affinity constant
nearly identical to that of the 1C10 Fab, whereas the eucaryotic
scFv fragment had a lower affinity with a specificity profile
identical to original mAb. The half-lives of the digoxin:scFv
complexes and the global specificity are compatible with
therapeutic use of this antibody fragment.
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1. Introduction
In the past decade, the development of immunoglobulin (Ig)
gene manipulation and expression systems has provided a
large number of recombinant antibodies (Abs) and Ab frag-
ments [1]. These engineered Abs have applications in many
¢elds such as immunodiagnosis [2,3], research [4], immuno-
scintigraphy [5], and mainly immunotherapy [6^8]. The small
Ab fragment scFv (single-chain Fv) is of considerable interest
in these ¢elds. scFv is a unique polypeptide composed of the
heavy chain variable region (VH) covalently linked to the light
chain variable region (VL) by a short £exible peptide of about
15 residues. It can be derived from phage-display libraries [9]
or hybridoma [10]. Furthermore, an scFv of desired speci¢city
can be engineered to modify its properties, e.g. a⁄nity [11].
Numerous scFvs have been produced for therapeutic needs,
including cancer treatment [12,13] and detoxication [14,15].
For detoxication, as well as for immunoscintigraphy, the
small size of the scFv (27 kDa) permits good tissue penetra-
tion and rapid di¡usion in the body. Furthermore, the ab-
sence of constant domains decreases the risk of immunogenic-
ity [8]. In cancerology, scFvs are frequently produced as
fusion proteins with an e¡ector [16] or as bivalent or bispeci¢c
Ab fragments [17].
Bacterial expression systems are currently used for scFv
production. High expression levels can be achieved in Esche-
richia coli (up to several hundred milligrams), but the counter-
part is an accumulation of aggregated material in the cyto-
plasm (inclusion bodies); a subsequent ‘tricky’ step of
refolding is then necessary [18]. Cell secretion methods, using
a signal peptide directing the scFv protein to the periplasmic
space, can obviate this [19]. The signal sequence is cleaved
during transport through the cytoplasmic membrane. Gener-
ally the secreted protein is then correctly folded and has a
homogeneous N-terminus [1] ; nevertheless, the yield is often
low and periplasmic inclusion bodies and dimers or higher
polymers can occur [20]. Alternative expression systems have
been used for scFv, including yeast [21^23], mammalian cells
[24], plants [25,26], and insect cells with the baculovirus vector
[27,28]. The latter o¡ers theoretically a strong advantage over
the other systems for therapeutic purposes. As far as it is
known, insect cells and baculovirus are devoid of pathogenic
or toxic compounds for humans; moreover, insect cells can be
grown in serum-free medium, i.e. without mammalian con-
taminants, leading to easy and safe puri¢cation. Chimeric
whole Ab, with mouse variable regions and human constant
regions, have been produced in insect cells for use in human
therapy [29,30].
We previously produced a monoclonal anti-digoxin anti-
body named 1C10 which has a high a⁄nity for digoxin
(0.23 nM) and broad speci¢city [31]. In particular, it recog-
nizes digoxin analogs (lanatoside C, deslanoside, digitoxin,
digitoxigenin) and all its active metabolites. This monoclonal
antibody (mAb) has been described as a powerful tool in the
treatment of life-threatening digoxin intoxications [32,33]. To
improve its kinetics in vivo, we have genetically engineered a
reduced sized mAb. We produced the 1C10 scFv in E. coli and
in the baculovirus/insect cell system. After ampli¢cation of the
VH and VL genes of the 1C10 hybridoma, the scFv was as-
sembled through the (Gly4Ser)3 linker and cloned either in the
pHEN-His vector or in an original baculovirus vector named
pBFv, each of which contains a signal peptide and a myc-
hexahistidine (His6) tag. The same S¢I and NotI cloning sites
were used in both vectors, leading to complete compatibility
between the phagemid and the baculovirus system.
We report here that the 1C10 scFv was produced in an
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active form in both E. coli and in the baculovirus/insect cell
system. The 1C10 scFv expressed in bacteria showed a di¡er-
ent ¢ne speci¢city pro¢le compared with the parental mAb.
The same scFv expressed in the baculovirus system showed
intact speci¢city but had lower a⁄nity for the hapten.
2. Materials and methods
2.1. Cell lines, bacterial strains and vectors
The 1C10 hybridoma and 1C10 mAb have been described previ-
ously [31]. The 1C10 Fab used as reference was obtained by papain
digestion [34]. Anti-myc tag 9E10 mAb, HB2151 E. coli strain and
pHEN1 phagemid [35] were kind gifts from Dr. G. Winter. Spodop-
tera frugiperda Sf9 insect cells were purchased from ATCC (CRL
1711); p118 plasmid and AcSLP10 baculovirus have been described
previously [36].
2.2. Cloning and sequencing of VH and VL 1C10 genes
Total RNA was extracted from 6U108 1C10 hybridoma cells using
the guanidium thiocyanate method as described by Chomczynski and
Sacchi [37]. Reverse transcription was performed with 2 Wg of total
RNA, the reverse transcriptase Superscript (GibcoBRL) and primers
OPP-SoFdQ1-3P (5P CAAAGATCTCAACCACAATCCCTGGGCA
3P) for cDNA heavy chain synthesis and OPP-SoCU3P (5P CGCGCA-
GATCTAACACTCATTCCTGTTGAAGC 3P) for cDNA light chain
synthesis. One Wl of ¢rst strand cDNA was used as matrix for the
PCR to amplify the 1C10 VH-CH1 and VK-CK genes in two separate
reactions using VentDNA polymerase (New England Biolabs) and the
following degenerate primers: for VH-CH1 ampli¢cation, OPP-
SoFdQ1-3P and OPP-SoVH-5P (5P GAGGT(C/G)CAGCTGCAG(C/
G)AGTC(T/A)GG 3P) ; for VK-CK ampli¢cation, OPP-SoCU-3P and
OPP-SoVU-5P (5P GA(C/T/A)ATTGAGCTCAC(C/A)CAG(T/A)CT-
CCA 3P). The ampli¢ed fragments were cloned in pUC19 in the
SmaI site and sequenced using the dideoxy chain termination method
[38] with the T7 sequencing kit (Pharmacia).
2.3. Construction of the baculovirus pBFv cassette
As described in Fig. 1A, a modi¢ed pUC19 plasmid containing a
unique BglII site in the HincII site of the polylinker was linearized
with BamHI and BglII. A BamHI/BglII oligonucleotide of 83 bp (Fig.
1B) was cloned into the digested pUC19 to obtain the pUC19/insert I
construction. This oligonucleotide contains the ¢rst 13 codons of the
cDNA of the mouse V47 VH gene signal sequence [39] followed by
S¢I and NotI sites. The 71 bp oligonucleotide (Fig. 1B) was then
inserted into pUC19/insert I, previously digested with NotI and BglII.
This oligonucleotide contains the myc tag and His6 tag sequences
between NotI and BglII sites. To construct the pBFv cassette,
pUC19/insert I+II was linearized with BamHI and BglII; the insert
I+II was then puri¢ed using the PCRprep Wizard puri¢cation kit
(Promega). The p118 plasmid, a p10 transfer vector containing a
unique BglII site downstream of the baculovirus p10 promoter [36],
was linearized with BglII. The pBFv transfer cassette was obtained by
cloning the insert I+II in the BglII site. Sequences of all the construc-
tions were veri¢ed on both strands.
2.4. Construction and cloning of the 1C10 scFv
VH and VK DNA were separately ampli¢ed using cloned Pfu
DNA polymerase (Stratagene) with speci¢c sets of primers:
VHBack1C10 (5P CATGCCATGACTCGCGGCCCAGCCGGCCAT-
GGCCCAGGTCCAAGCCGCAGAGTCCGG 3P), VHFor1C10 (5P
GCCAGAGCCACCTCCGCCTGAACCGCCTCCACCTGCAGAG-
ACAGTGACCAGAGTCC 3P), VUBack1C10 (5P TCAGGCG-
GAGGTGGCTCTGGCGGTGGCGGATCGGACATCCAGATGA-
CCCAGACTCCATCCTCCTTATCT 3P) and VUFor1C10 (5P
GAGTCATTCTGCGGCCGCCCGTTTGATTTCCAGCTTGGTGC-
CTCC 3P). VHFor1C10 and VUBack1C10 are overlap primers con-
taining sequences encoding the (Gly4Ser)3 linker peptide (underlined),
which were designed to be complementary at their extremities, thus
allowing subsequent annealing of the ampli¢ed VH and VL regions.
VHBack1C10 and VUFor1C10 contain the S¢I and NotI restriction
sites, respectively, for the scFv cloning (italics). The VH and VU genes
obtained after 30 cycles of PCR (94‡C 1 min, 55‡C 1 min, 72‡ 2 min)
were gel puri¢ed; next, an overlapping PCR was performed to con-
struct the scFv gene under the same conditions, but with the
VHBack1C10 and VUFor1C10 primers. The scFv DNA was gel pu-
ri¢ed, cleaved successively with S¢I and NotI, and inserted into
pHEN-His linearized using the same restriction enzymes. pHEN-His
was derived from pHEN1, through addition of a hexahistidine peptide
(His6) just after the myc sequence using site-directed mutagenesis. The
recombinant pHEN-His (BM28) was electroporated into competent
E. coli HB2151 cells and positive clones were checked by PCR using
VHBack1C10 and VUFor1C10 oligonucleotides.
The scFv DNA was cloned into the pBFv vector using the same S¢I
and NotI restriction sites, yielding pBFv1C10. The nucleotide se-
quence of 1C10 scFv cloned either in pHEN-His or in pBFv was
veri¢ed and is presented in Fig. 2.
2.5. Expression and puri¢cation of 1C10 scFv
For procaryotic expression, 1:50 dilution of an overnight culture of
HB2151 transfected with the BM28 vector was grown at 37‡C to an
OD600nm of 0.6 in 2UTY medium containing 100 Wg/ml ampicillin and
5% glycerol, induced with 0.5 mM ¢nal IPTG and shaken for 2 h at
22‡C. The periplasm containing soluble scFv was extracted according
to the procedure described by Skerra and Pluºckthun [40] and stored at
+4‡C. Periplasmic scFv was puri¢ed on an anti-myc a⁄nity column
using 9E10 mAb coupled to a CNBr-activated Sepharose 4B (Phar-
macia). Bound scFv was eluted with 3 M glycine pH 2.2, 0.5 M NaCl,
and the pH was immediately neutralized with a solution of 1 M Tris.
Fractions were assayed by ELISA (described below) and their purity
veri¢ed on a 15% SDS-PAGE using the procedure of Laemmli [41].
The puri¢ed scFv was dialyzed at +4‡C against water containing 5%
saccharose.
Insect cell expression of recombinant scFv was performed as pre-
viously described [30]. Brie£y, Sf9 cells were cotranfected with 5 Wg of
pBFv1C10 and 500 ng of the puri¢ed DNA of the AcSLP10 baculo-
virus, yielding after the recombination event a baculovirus expressing
the 1C10 scFv under the control of the p10 promoter. This virus was
selected by plaque assay as an occlusion body-negative virus. Sf9 cells
grown in serum-free medium were then infected with the recombinant
baculovirus at a multiplicity of infection of 2 in a spinner culture (106
cells/ml). Supernatant (500 ml) was harvested 10 days post-infection.
This supernatant (SN) was puri¢ed by IMAC on a nickel-NTA agar-
ose gel (Qiagen) using a batch procedure. Ten ml of SN were incu-
bated for 1 h at +4‡C on 0.5 ml of nickel-NTA gel equilibrated twice
with 5 ml of a 25 mM Tris, 500 mM NaCl, pH 7.5 bu¡er (TN)
containing 5 mM imidazole. After centrifugation at 700Ug and two
washes in 5 ml of TN, 25 mM imidazole, the scFv was eluted twice
with 0.5 ml of TN, 500 mM imidazole, dialyzed in water containing
5% saccharose, and checked by ELISA for activity and electrophoresis
for purity.
Protein content was determined by the microBCA method (Pierce)
using bovine serum albumin as standard, and by measuring the ab-
sorbance at 280 nm. A 1 mg/ml solution of the 1C10 scFv was found
to have an absorbance of 1.9, calculated according to Mach et al. [42].
Both methods gave the same value.
2.6. Detection of scFv anti-digoxin activity and determination of
speci¢city
An indirect ELISA procedure was performed as previously de-
scribed [43] to detect the scFv anti-digoxin activity in periplasm, Sf9
supernatant, or pure preparations. Brie£y, microtiter plates coated
with 5 Wg/ml of digoxin-BSA conjugate (Dig-BSA) were incubated
with di¡erent dilutions of scFv preparations in PBS-0.1% Tween for
2 h at 37‡C. Bound scFv was detected using the 9E10 anti-myc mAb
and a horseradish peroxidase-labeled anti-mouse IgG conjugate (Sig-
ma).
The speci¢city of the scFv was determined by inhibition ELISA as
follows: various concentrations (from 1033 to 10311 M) of digoxin
analogs (Sigma) were preincubated overnight at +4‡C with periplasm
or Sf9 supernatant. Digoxin, other cardiac glycosides (digitoxin, gi-
toxin, lanatoside C, acetylstrophantidin, ouabain), active metabolites
(digoxigenin, digitoxigenin), and endogenous steroids (progesterone,
testosterone, cortisone) were tested. The dilution of each scFv sample
was chosen so as to give a ¢nal absorbance of approximately 1.0 in
absence of inhibitor. One hundred Wl of each mixture was added to
the Dig-BSA-coated wells and the procedure described above was
followed. The ratio of the analog concentration giving 50% inhibition
to the digoxin concentration required to give 50% inhibition re£ects
the relative a⁄nity of each analog [31]. The speci¢city pro¢le of the
puri¢ed 1C10 mAb obtained in the same experiment served as refer-
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ence; the 1C10 mAb was detected directly with the horseradish per-
oxidase conjugate.
2.7. A⁄nity determination
The kinetic parameters, association rate constant (ka), and dissoci-
ation rate constant (kd), were determined by surface plasmon reso-
nance (SPR) analysis, using a BIAcore 1000 instrument (Biacore AB).
The apparent equilibrium dissociation constant Kd, which is the ratio
of kd/ka, was calculated using the BIAevaluation 3.0 software. We
used a sensor chip surface covered with the NTA ligand for nickel
(Biacore AB) to immobilize the 1C10 scFv through its His6 tail : after
washing the sensor chip surface with 350 mM EDTA, nickel chloride
(0.5 mM in PBS) was added, and then the pure scFv sample was
injected. Sensorgrams representative of the ¢xation of the Dig-BSA
conjugate on the immobilized scFv were analyzed. It should be noted
that digoxin alone could not be used because its low molecular mass
(781 Da) does not give any registrable refraction index variation on
the BIAcore 1000. To validate the nickel-NTA sensor chip, one of the
E. coli samples was analyzed through a conventional procedure: di-
goxin was immobilized on a CM5 sensor chip (Biacore AB) through
its oxidized sugar moiety as reported earlier [44], then pure scFv was
added, and its binding was analyzed. The Kd value was exactly the
same as that found when the nickel-NTA sensor chip was used (data
not shown). The Fab, obtained by cleavage of the parental mAb, was
analyzed on the digoxin-coupled sensor chip, and served as reference.
3. Results
3.1. Sequence of the 1C10 scFv gene
The nucleotide sequences of 1C10 scFv cloned in pHEN-
His and in pBFv were identical and the VH and VK sequences
were the same as those obtained after cloning of VH-CH1 and
VK-CK in pUC19 (data not shown). As described in Fig. 2,
sequence comparison using the Kabat database showed that
the VH region of the 1C10 Ab belongs to the subgroup IIB
and the VH gene to the J558 family (91.1% homologous to the
closest J558-197 germline gene). The VH region has accumu-
lated a total of 30 somatic mutations, leading to 14 amino
acid changes, during the immunization process. The H chain
CDR3 is composed of the DSP2.2 D segment and the addi-
tion of 12 nucleotides, 9 upstream from the D gene and 3
downstream. The 1C10 Ab uses the JH3 gene with 2 muta-
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Fig. 1. A: Construction of the pUC19/insert I+II plasmid and cloning of insert I+II into the BglII site of p118, leading to the scFv cassette
transfer vector pBFv. B: Sequence of the 83 bp oligonucleotide inserted in the BamHI/BglII site of pUC19 for the construction of pUC19/insert
I; sequence of the 71 bp oligonucleotide inserted in the NotI/BglII site of pUC19/insert I for the construction of pUC19/insert I+II.
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tions. The VL region belongs to the VK subgroup V (family
VK9), showing 99.1% homology with the MOPC41 germline
gene, and uses the JK1 gene. The VK region accumulated only
6 somatic mutations, leading to 2 amino acid changes local-
ized in the framework regions.
Sequence comparison of the 1C10 variable regions and
other anti-digoxin antibodies shows that signi¢cant homology
can only be found with the 2C2 Ab, another anti-digoxin
mAb generated in our lab from the same fusion experiment
as 1C10 mAb [31,43]. The VH regions of these Abs show
92.7% homology, corresponding to 17 amino acid di¡erences,
5 of them being concentrated in the CDR2 region. Surpris-
ingly, the CDR3-JH3 segment of 1C10 VH is totally identical,
except one silent mutation, to the corresponding segment of
the 2C2 Ab. The VL regions of 1C10 and 2C2 Ab have 95.6%
homology, corresponding to 7 amino acid di¡erences, 4 of
them being concentrated in the CDR regions.
Other anti-digoxin antibody VH regions show less than 70%
homology with the 1C10 VH, even the 26.10 Ab described by
Near et al. [45], which belongs to the same J558 family. It
should be noted that among the antibodies that match with
the 1C10 CDR3, and a fortiori with the 2C2 CDR3, several
Abs directed against haptens have been described such as anti-
alprenolol [46] and anti-haloperidol [47].
3.2. Cloning and expression of 1C10 scFv
The 1C10 scFv was constructed using speci¢c primers and
overlapping PCR to incorporate the (Gly4Ser)3 linker. It was
cloned in a procaryotic vector, the phagemid pHEN-His, or in
an original baculovirus transfer vector named pBFv (Fig. 1).
This pBFv vector contains a P10 promoter, a signal sequence
for secretion, tags for detection and puri¢cation, and unique
restriction sites S¢I and NotI. These characteristics allow easy
cloning of a PCR-ampli¢ed scFv obtained from a hybridoma
or a bacterial library into this vector. Furthermore, the trans-
fer from the procaryotic to the eucaryotic expression systems
is facilitated using the pHEN/pBFv compatibility. The 1C10
scFv was easily transferred from pHEN-His to pBFv in a
single cloning step, then recombination of 1C10 pBFv with
baculovirus DNA containing the polyhedrine gene under the
control of P10 promoter was performed in Sf9 cells. The scFv
was then secreted into serum-free culture medium of the Sf9
cells. After puri¢cation of 200 ml Sf9 SN on a nickel column,
2 mg of pure scFv was obtained, corresponding to a yield of
10 mg/l. Puri¢cation of the SN by a⁄nity chromatography on
an anti-myc column yielded a pure scFv fragment but without
any binding activity to dig-BSA (data not shown).
In pHEN-His, the PelB signal peptide upstream from the
scFv directs the expression to the periplasmic compartment.
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Fig. 2. A: Nucleotide and B: predicted amino acid sequences of the 1C10 anti-digoxin scFv compared with the most homologous germline
gene and the 2C2 anti-digoxin scFv. Amino acid sequences are given in the one letter code. The complementarity determining regions (CDR)
of VH and VL are highlighted and the linker peptide (Gly4Ser)3 is in italics. Dashes in sequences indicate identity with the residues given in the
top line. J segments and D genes are boxed.
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A⁄nity chromatography on an anti-myc column yielded to
200 Wg pure scFv per 20 ml periplasm (corresponding to 1 l
of culture). Puri¢cation on a nickel column was tested but did
not lead to enough pure fractions (data not shown).
Both pure scFvs were controlled on 15% SDS-PAGE (Fig.
3) and migrated with a higher apparent molecular mass (33
kDa) than the calculated one (28 212 Da), as already reported
[48]. A very low quantity of dimer is present in pure prepa-
rations. As demonstrated in Fig. 4, pure scFv expressed either
in bacteria or in baculovirus retained the digoxin binding
activity.
3.3. A⁄nity
A⁄nity constants were determined on BIAcore 1000 by
real-time interaction analysis, with the enzymatically cleaved
Fab as reference and are presented in Table 1. Using the
BIAevaluation 3.0 software, the global ¢t analysis [49] showed
that the experimental and theoretical curves can be superim-
posed, with most of the residuals being less than 0.5 resonance
unit, indicating that the curves are monoexponential (data not
shown). These observations suggest that the scFv preparations
are mainly composed of monomers. The a⁄nity of the 1C10
E. coli secreted scFv was close to the a⁄nity of the Fab. The
insect cell secreted 1C10 scFv had a 8.5-fold lower a⁄nity
than that of the Fab, mainly due to a faster dissociation.
The 4.5-fold di¡erence between the scFv Kd values can be
explained by a lower association rate between the hapten
and the baculovirus fragment than with the E. coli secreted
fragment. This di¡erence is in agreement with the ELISA
curve (Fig. 4), where equal amounts of pure scFv are shown
to give a lower detection signal in the baculovirus system than
in the bacterial one.
Calculated half-lives of the scFv:digoxin complexes from
the kd values showed that they are still compatible with a
pharmacological use of the scFv (52 and 40 min for the pro-
caryotic and eucaryotic fragments, respectively), even though
they are lower than that of the Fab (170 min).
3.4. Speci¢city
Table 2 shows the ¢ne speci¢city properties of the recombi-
nant scFv fragments and the parental mAb. As described
previously [31], 1C10 mAb recognizes digoxin, digitoxin and
their active deglycosylated metabolites, but does not bind en-
dogenous steroid analogs nor other cardiac glycosides. This
pro¢le is maintained when the 1C10 mAb is diluted either in
periplasm obtained after induction of bacteria transfected
with pHEN-His alone or in supernatant of Sf9 cells infected
with wild-type baculovirus (data not shown), suggesting that
the binding characteristics are not in£uenced by the media.
The overall speci¢city of the parental mAb is conserved in
both scFvs, i.e. binding to the related glycosides and metab-
olites, absence of binding to the endogenous steroid analogs
and the more structurally distant glycosides. The baculovirus-
expressed scFv has the same ¢ne speci¢city pro¢le as that of
the 1C10 mAb, whereas the 1C10 scFv from the E. coli peri-
plasmic extract shows signi¢cant changes in its ¢ne speci¢city
properties, in particular with digitoxin and the deglycosylated
metabolites (digoxigenin, digitoxigenin). Firstly, the E. coli
scFv binds to digitoxin with lower a⁄nity than to digoxin.
Secondly, the procaryotic scFv binds the aglycone molecules
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Fig. 3. Silver-stained SDS-PAGE of sf3 culture supernatant contain-
ing 1C10 scFv (lane 2), puri¢ed 1C10 scFv (lane 3) from baculovi-
rus-infected insect cells, periplasmic extract containing 1C10 scFv
(lane 4) and puri¢ed 1C10 scFv from bacteria (lane 5). Molecular
weight markers are presented on lane 1.
Fig. 4. ELISA binding activity of puri¢ed baculovirus- (R) and
E. coli- (b) expressed 1C10 scFv on an adsorbed Dig-BSA conju-
gate.
Table 1
A⁄nity constants of the recombinant 1C10 scFv expressed in E. coli and insect cells and the 1C10 Fab, as determined by BIAcore analysis
Antibody fragment Association rate constant
(ka, M31 s31)
Dissociation rate constant
(kd, s31)
Apparent equilibrium dissociation constant
(Kd, M)
1C10 Fab (2.48 þ 0.05)U104a (7.00 þ 0.03)U1035 (2.82 þ 0.07)U1039
1C10 scFv expressed in E. coli (2.40 þ 0.15)U104 (1.22 þ 0.25)U1034 (5.04 þ 1.03)U1039
1C10 scFv expressed in insect cells (2.09 þ 0.04)U104 (5.13 þ 0.03)U1034 (24.5 þ 1.15)U1039
aResults are the means þ S.E. obtained from three separate experiments, using puri¢ed samples.
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with higher a⁄nity than the corresponding glycosides, sug-
gesting that the speci¢city properties of the E. coli-expressed
fragment is in£uenced by the sugar moiety, unlike the intact
mAb [31]. Although the two scFv preparations were diluted to
give a ¢nal absorbance of 1.0 in the inhibition ELISA experi-
ments, the di¡erent protein content of these preparations
might have in£uenced their speci¢city.
4. Discussion
1C10 mAb is a high a⁄nity monoclonal antibody whose
speci¢city is of great interest for medical purposes, namely,
detoxication [31] : this Ab recognizes the cardiac glycosides
digoxin and digitoxin, and their active metabolites, the more
active ones being also highly toxic. The in vitro and in vivo
e⁄ciency of this mAb in digoxin neutralization has been pre-
viously demonstrated by Scherrmann et al. [32,33].
Since mutations resulting from antigen-driven maturation
provide information on the parts of the Ab variable regions
important in a⁄nity and speci¢city, we analyzed the nucleo-
tide sequence of the variable regions of this particular mAb.
Sequence comparison shows that this Ab is close to another
anti-digoxin mAb named 2C2 generated from the same fusion
(95% homology). These two mAbs use identical germline
genes, J558-197 for the VH region and MOPC41 for the VL
region. They recognize digoxin with comparable a⁄nities (Kd :
0.23 and 0.17 nM for 1C10 and 2C2, respectively), but their
¢ne speci¢city properties, i.e. binding to digoxin metabolites
and analogs, are completely distinct [31]. The other anti-di-
goxin antibodies described in the literature [45,50,51] do not
match signi¢cantly with the 1C10 mAb.
Many authors have demonstrated that the ¢ne speci¢city
properties of antibodies are mostly due to mutations in the
heavy chain variable region [52^54] and that the a⁄nity is also
often borne by this part of the molecule [55]. In particular the
CDR3 of the VH region (CDR3H) is described to play a
major role in Ab speci¢city, not only for anti-digoxin or
anti-hapten Abs [52,56], but also for many other Abs
[53,54,57]. The light chain might nevertheless contribute to
speci¢city and a⁄nity; in particular the VJ junction seems
to be critical [51,54]. In our case, the 1C10 VH gene is highly
mutated (14 amino acid changes compared with the germline
gene), whereas VL region has only 2 amino acid changes in the
framework segments, suggesting that the VL chain has little
in£uence on the speci¢city and a⁄nity of this Ab. The 1C10
CDRH3 has two point mutations, only one leading to an
amino acid change, and shares exactly the same JH heavy
chain segment as the 2C2 mAb in spite of distinct speci¢cities,
strongly suggesting that this CDR3 gene segment is not in-
volved in ¢ne discrimination between the digoxin analogs.
Interestingly, the CDR2 heavy chain genes of VH 1C10 and
2C2 are the most mutated CDRs, with 5 di¡erent residues out
of 17 between these two mAbs. This particular CDR might
thus be involved in the ¢ne speci¢city of these two mAbs. The
role of mutations in CDRH2 on Ab speci¢city has already
been proposed by Jahn et al. [53]. However, we cannot ex-
clude that the framework1 and CDR1 are also implicated, as
described previously [53,57]. Mutagenesis analysis as well as
structural studies on the scFv:digoxin complexes should shed
light on this issue.
In this study, we used a eucaryotic expression system
adapted to a procaryotic vector for Ab fragment production
and phage display. This allowed a facile transfer of the scFv
genes and the expression of scFv in insect cells. The baculo-
virus expression system seems to be a promising way to pro-
duce molecules for therapeutic purposes because of its capa-
bility for a high production level [58] and absence of known
intrinsic or secreted molecules toxic for man. This is in con-
trast with E. coli which can release endotoxins, or plants
which contain toxic or allergenic compounds. Furthermore,
Sf9 cells can be accustomed to grow without serum thus
avoiding the presence of mammalian contaminants [58].
Only few scFv Ab fragments have been expressed until now
with this system [27,28]. To have complete compatibility be-
tween the procaryotic and baculovirus vectors for scFv clon-
ing, we constructed an original baculovirus transfer cassette
named pBFv, containing the same S¢I and NotI sites as the
pHEN vector, a phagemid often described in the literature to
construct Ab libraries [35]. After selection on antigen, the
scFv cloned in the pHEN vector could then be easily trans-
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Table 2
Speci¢city pro¢le of 1C10 scFv expressed in E. coli and insect cells
Analog 1C10 scFv expressed in E. coli 1C10 scFv expressed in insect cells 1C10 mAb
Cardiac glycosides
Digoxin 1.0a 1.0 1.0
Digitoxin 4.7 þ 0.7 0.3 þ 0.04 0.9
Lanatoside C 0.5 þ 0.1 0.3 þ 0.1 0.2
Gitoxin 116.0 þ 14.0 47.4 þ 26.0 40.0
Acetylstrophantidin NDc s 1000 s 1000
Ouaba|ºn s 1000 s 1000 s 1000
Active metabolites
Digoxigenin 0.3 þ 0.04b 1.1 þ 0.4 2.1
Digitoxigenin 1.2 þ 1.0 16.2 þ 4.9 17.4
Endogenous steroids
Progesterone s 1000 s 1000 s 1000
Testosterone s 1000 s 1000 s 1000
Cortisone ND s 1000 s 1000
aResults are expressed as the ratio of analog concentration giving 50% inhibition of scFv binding to digoxin, to the digoxin concentration giving
50% inhibition (arbitrarily set at 1.0).
bEach value is the mean þ S.E. of ratios obtained from triplicate wells in three separate experiments.
cND, not determined.
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ferred to pBFv for expression in the baculovirus system. To
evaluate the potentialities of these two systems of production,
we constructed and cloned an anti-digoxin scFv either in
pHEN or in the new pBFv.
We chose to directly express the 1C10 scFv in a functional
form, i.e. secreted either in the supernatant of Sf9 or in the E.
coli periplasm and to compare these two systems of produc-
tion. The yield of pure 1C10 scFv was higher in the baculo-
virus expression system than in the bacteria (10 and 0.2 mg/l
culture, respectively) and was also higher than other scFv
£ask productions in baculovirus described until now [27,28].
In addition, the a⁄nities of these two genetically identical
scFvs were di¡erent: 1C10 scFv from baculovirus showed 5-
fold lower binding to digoxin than that from E. coli, essen-
tially because of a lower association rate constant. It should
be noted that the a⁄nity of 1C10 E. coli-expressed scFv was
in the same order of magnitude as that of the 1C10 Fab. To
our knowledge, this is the ¢rst time that binding of an Ab to a
steroid hapten is analyzed by BIAcore. It is also the ¢rst time
that an NTA sensor chip is used to determine the kinetics of
an scFv binding to antigen. This format is a fast and conven-
ient way of a⁄nity determination because it permits calcula-
tion of the binding constants of a His-fusion protein in a
complex medium without any knowledge of its concentration.
Surprisingly, 1C10 scFv expressed in bacteria had a ¢ne
speci¢city pro¢le di¡erent from that of the scFv and the pa-
rental mAb produced in eucaryotic systems. Furthermore, we
found an apparent con£icting result since the scFv expressed
in baculovirus had a speci¢city pro¢le identical to that of the
parental mAb but with lower a⁄nity for digoxin than the
scFv expressed in the procaryotic system. This suggests that
the eucaryotic fragment binding site folding is closely related
to the parental binding site, the lower a⁄nity being partly a
consequence of the absence of constant domains [59,60]. The
changes in binding of the E. coli scFv fragment to digitoxin
and the aglycone molecules might be due to slight variations
in the ¢tting to carbon-12 in the digoxin molecule and to the
presence of the digitoxoses, resulting in an increase of the
association rate constant for digoxin. Slight conformational
changes of this protein produced in the two expression sys-
tems might have several origins: (i) the di¡erent procedures
used to purify the scFv may have a¡ected their a⁄nity, even
though preliminary equilibrium dialysis indicated that the
fraction of active binding sites in each scFv preparation was
nearly identical (J-M. Scherrmann, personal communication),
(ii) changes in the post-translational status are probably in-
volved, e.g. glycosylations which can occur in the baculovirus
system, but not in the bacterial system; there is no potential
N-glycosylation site in the amino acid sequence, but O-glyco-
sylation sites are present; (iii) in£uence of an incompletely
cleaved signal peptide cannot be excluded, (iv) our results
can also be a consequence of distinct chaperoning between
the eucaryotic and procaryotic cells, leading to changes in
the 1C10 binding site conformation, (v) in£uence of the ex-
pression temperature (28‡C in Sf9 cells, 22‡C in E. coli) on the
folding is also possible.
A previous report described a di¡erent speci¢city pro¢le
between the scFv expressed in bacteria and the Fab obtained
from the same mAb [10], but no speci¢city di¡erence has been
described until now between scFvs showing the same nucleo-
tidic sequence and expressed in eucaryotic and procaryotic
vectors [27,28]. Nevertheless, the majority of scFvs described
in the literature do not show any change in the speci¢city
pro¢le compared with the parental mAb [60,61]. The possibil-
ity cannot excluded however that ¢ne variations do exist but
have not yet been identi¢ed. It should be noted that the di-
goxin model is interesting for this purpose because of the
existence of a large panel of close analogs di¡ering by a
unique substitution on the steroid moiety.
The choice of the expression system appears to be a key
factor in the production of functional scFv fragments of ther-
apeutic interest. Information on the a⁄nity and speci¢city of
the antibody fragment is necessary to validate the choice. For
the 1C10 scFv, we demonstrated that the baculovirus/insect
cell system o¡ers advantages in comparison with the E. coli
system in terms of yield and speci¢city. In addition, our new
baculovirus vector, using the same cloning sites as the pHEN
phagemid, proved to be very e⁄cient for rapidly producing
antibody fragments in insect cells.
1C10 mAb has been shown to be of great therapeutic in-
terest [31], but it cannot be used because of its large size. The
results obtained here with the 1C10 scFv, namely, the half-life
of the digoxin:scFv complex and the ¢ne speci¢city pro¢le,
indicate that this Ab fragment could be a powerful tool for
immunodetoxication of patients who have absorbed lethal
doses of digoxin.
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